Home LiteratureArticle Details
PMID: 2497014 Published · ppublish English Clinical Trial Journal Article Review

In vitro and in vivo evaluation of antifungal agents.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology ·Vol. 8 ·No. 4 ·1989-04-00 ·Pages 352-61

Espinel-Ingroff A, Shadomy S

Abstract

The evaluation of any antifungal agent involves the determination of its in vitro and in vivo activity against pathogenic and/or opportunistic fungi. The in vitro evaluation is followed by an in vivo evaluation in animal models, and clinical trials in humans. From the first report of the efficacy of the iodides for the treatment of sporotrichosis (1903) until the introduction of the imidazoles (azoles, 1960s), the number of antifungal agents available was very limited, including griseofulvin (1939), nystatin (1950), amphotericin B (1956), and flucytosine (1964). This paper briefly reviews the status of the antifungal agents currently used, and gives a more in depth evaluation of progress during recent years in the search for new antifungal drugs. Efforts to improve the efficacy of the current antifungal agents are also reviewed.

MeSH Terms
Animals Antifungal Agents/pharmacology,therapeutic use Clinical Trials as Topic Drug Evaluation Drug Evaluation, Preclinical Fungi/drug effects Humans Microbial Sensitivity Tests Mycoses/drug therapy Opportunistic Infections/drug therapy
Chemicals
Antifungal Agents
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Espinel-Ingroff A
Division of Infectious Diseases, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298-0504.
Shadomy S
References (77)
77 references, click to expand
  1. Resistance to polyene antibiotics and correlated sterol changes in two isolates of Candida tropicalis from a patient with an amphotericin B-resistant funguria.
    J Infect Dis. 1974 Jan;129(1):53-8 PMID: 4587944
  2. Enhanced efficacy of amphotericin B and rifampicin combined in treatment of murine histoplasmosis and blastomycosis.
    J Infect Dis. 1976 Jun;133(6):663-8 PMID: 932494
  3. Overview of medically important antifungal azole derivatives.
    Clin Microbiol Rev. 1988 Apr;1(2):187-217 PMID: 3069196
  4. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis.
    Am J Med. 1987 Aug;83(2):236-42 PMID: 3303926
  5. Toxicity of intravitreal injection of fluconazole in the rabbit.
    Can J Ophthalmol. 1987 Oct;22(6):304-6 PMID: 2827871
  6. Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice.
    Antimicrob Agents Chemother. 1985 Dec;28(6):815-8 PMID: 3002246
  7. R 51211 (itraconazole) therapy of murine cryptococcosis.
    Sabouraudia. 1984;22(6):445-53 PMID: 6098031
  8. Allylamines: topical and oral treatment of dermatomycoses with a new class of antifungal agents.
    Acta Derm Venereol Suppl (Stockh). 1986;121:155-60 PMID: 3459341
  9. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections.
    Drugs. 1982 Jan-Feb;23(1-2):1-36 PMID: 6276122
  10. Clotrimazole (Bay b 5097): in vitro and clinical pharmacological studies.
    Antimicrob Agents Chemother. 1972 Dec;2(6):423-6 PMID: 4677595
  11. In-vitro studies with four new antifungal agents: BAY n 7133, bifonazole (BAY h 4502), ICI 153,066 and Ro 14-4767/002.
    Sabouraudia. 1984;22(1):7-15 PMID: 6322364
  12. Obfuscation of the activity of antifungal antimicrobics by culture media.
    J Infect Dis. 1972 Oct;126(4):353-61 PMID: 4561725
  13. Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results.
    Rev Infect Dis. 1987 Jan-Feb;9 Suppl 1:S71-6 PMID: 3027850
  14. Antifungal activity of the allylamine derivative terbinafine in vitro.
    Antimicrob Agents Chemother. 1987 Sep;31(9):1365-8 PMID: 3674847
  15. Deep infections from Petriellidium boydii treated with miconazole.
    JAMA. 1979 Jan 19;241(3):272-3 PMID: 758531
  16. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.
    Antimicrob Agents Chemother. 1986 Apr;29(4):579-83 PMID: 3010846
  17. Culture media for the study of the effects of azole derivatives on germ tube formation and hyphal growth of C. albicans.
    Mykosen. 1986 Feb;29(2):76-81 PMID: 3515172
  18. Treatment of experimental murine candidiasis with liposome-associated amphotericin B.
    Sabouraudia. 1984;22(2):163-6 PMID: 6729660
  19. Mode of action of 5-fluorocytosine and mechanisms of resistance.
    Chemotherapy. 1975;21(3-4):113-30 PMID: 1098864
  20. Antifungal agents: recent developments.
    Annu Rev Microbiol. 1977;31:291-308 PMID: 334040
  21. Sporotrichosis in Queensland: a review of 37 cases at the Royal Brisbane Hospital.
    Australas J Dermatol. 1979 Apr;20(1):14-22 PMID: 475693
  22. Development of amphotericin B liposomes bearing antibody specific to Candida albicans.
    Mycopathologia. 1988 Jan;101(1):37-45 PMID: 3281020
  23. Inhibition of 14 alpha-sterol demethylase activity in Candida albicans Darlington does not correlate with resistance to azole.
    J Med Vet Mycol. 1987 Oct;25(5):329-33 PMID: 3323450
  24. Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis.
    Antimicrob Agents Chemother. 1987 Dec;31(12):1897-900 PMID: 3439798
  25. In vitro and in vivo anti-Candida activity and toxicology of LY121019.
    J Antibiot (Tokyo). 1984 Sep;37(9):1054-65 PMID: 6389460
  26. Improved method for estimation of azole antifungal inhibitory concentrations against Candida species, based on azole/antibiotic interactions.
    J Med Vet Mycol. 1986 Aug;24(4):305-11 PMID: 3746584
  27. Streptomyces nodosus sp. n., the amphotericin-producing organism.
    J Bacteriol. 1963 Feb;85:436-9 PMID: 13994057
  28. The effect of the morpholine derivate amorolfin (Roche 14-4767/002) on the ultrastructure of Candida albicans.
    Mykosen. 1987 Nov;30(11):528-40 PMID: 3328047
  29. Synergistic antifungal activity and reduced toxicity of liposomal amphotericin B combined with gramicidin S or NF.
    Antimicrob Agents Chemother. 1987 Dec;31(12):1978-81 PMID: 2449867
  30. Activity of amphotericin B, 5-fluorocytosine, and rifampin against six clinical isolates of Aspergillus.
    Antimicrob Agents Chemother. 1976 Jun;9(6):915-9 PMID: 820247
  31. Chemotherapeutic activity of 5-fluorocytosine and amphotericin B against Candida albicans in mice.
    Antimicrob Agents Chemother. 1973 Sep;4(3):306-8 PMID: 4586144
  32. Fungistatic and fungicidal effects of amphotericin B, ketoconazole and fluconazole (UK 49,858) against histoplasma capsulatum in vitro and in vivo.
    Mykosen. 1987 Apr;30(4):186-94 PMID: 3035371
  33. Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients.
    J Med Vet Mycol. 1988 Feb;26(1):67-71 PMID: 2837559
  34. Evaluation of in vitro antifungal activity of LY121019.
    Eur J Clin Microbiol Infect Dis. 1988 Feb;7(1):77-80 PMID: 3132385
  35. Miconazole in cryptococcosis and systemic candidiasis: a word of caution.
    Ann Intern Med. 1981 May;94(5):708-9 PMID: 7235405
  36. Treatment of systemic mycoses with ketoconazole: studies of ketoconazole serum levels.
    Mykosen. 1986 May;29(5):195-209 PMID: 3736588
  37. Imidazole therapy of coccidioidal meningitis in children.
    Pediatr Infect Dis J. 1988 Jan;7(1):40-4 PMID: 3340457
  38. Synergism of polyene antibiotics with 5-fluorocytosine.
    Chemotherapy. 1978;24(1):2-16 PMID: 338264
  39. In-vitro studies with SF 86-327, a new orally active allylamine derivative.
    Sabouraudia. 1985 Apr;23(2):125-32 PMID: 2990057
  40. Mycoses caused by Candida lusitaniae.
    Rev Infect Dis. 1987 Sep-Oct;9(5):1006-12 PMID: 3317728
  41. Comparison of the in vitro antifungal activities of miconazole and a new imidazole, R41,400.
    J Infect Dis. 1978 Aug;138(2):245-8 PMID: 681800
  42. Combined in vitro effect of amphotericin B and rifampin on Cryptococcus neoformans.
    Antimicrob Agents Chemother. 1981 Jan;19(1):196-8 PMID: 7018384
  43. Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice.
    Chemotherapy. 1982;28(6):461-79 PMID: 6297858
  44. Itraconazole in the treatment of human mycoses: review of three years of clinical experience.
    Rev Infect Dis. 1987 Jan-Feb;9 Suppl 1:S146-52 PMID: 3027842
  45. Synergistic action of amphotericin B and rifampin against Candida species.
    J Infect Dis. 1976 Feb;133(2):206-9 PMID: 1245767
  46. Itraconazole treatment of murine aspergillosis.
    Sabouraudia. 1985 Jun;23(3):219-23 PMID: 2992106
  47. In vitro studies with R 51,211 (itraconazole).
    Antimicrob Agents Chemother. 1984 Jul;26(1):5-9 PMID: 6089654
  48. Microtiter broth dilution method for yeast susceptibility testing with validation by clinical outcome.
    J Clin Microbiol. 1986 Oct;24(4):600-6 PMID: 3771749
  49. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study.
    J Infect Dis. 1985 Apr;151(4):704-10 PMID: 3973417
  50. Multicenter evaluation of four methods of yeast inoculum preparation.
    J Clin Microbiol. 1988 Aug;26(8):1437-41 PMID: 3049651
  51. Further in vitro studies with 5-fluorocytosine.
    Infect Immun. 1970 Oct;2(4):484-8 PMID: 16557866
  52. Effect of medium composition on results of macrobroth dilution antifungal susceptibility testing of yeasts.
    J Clin Microbiol. 1986 Oct;24(4):507-11 PMID: 3533974
  53. [In vitro sensitivity of Aspergillus to terbinafine: comparative study on amphotericin B, 5-fluorocytosine and ketoconazole].
    Pathol Biol (Paris). 1988 Feb;36(2):139-43 PMID: 3279381
  54. Comparative in vitro and in vivo evaluation of N-D-ornithyl amphotericin B methyl ester, amphotericin B methyl ester, and amphotericin B.
    Antimicrob Agents Chemother. 1987 Nov;31(11):1756-60 PMID: 3324961
  55. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections.
    Antimicrob Agents Chemother. 1987 Dec;31(12):1901-3 PMID: 3439799
  56. Activity of terbinafine in experimental fungal infections of laboratory animals.
    Antimicrob Agents Chemother. 1987 Oct;31(10):1558-61 PMID: 3435103
  57. Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods.
    Antimicrob Agents Chemother. 1987 Sep;31(9):1343-7 PMID: 3674846
  58. Two antifungal agents produced by a soil actinomycete.
    Science. 1950 Oct 13;112(2911):423 PMID: 14781786
  59. Comparison of fluconazole and amphotericin B in treating histoplasmosis in immunosuppressed mice.
    Antimicrob Agents Chemother. 1987 Dec;31(12):2005-6 PMID: 2830843
  60. Azole resistance in Candida albicans.
    Sabouraudia. 1984;22(1):53-63 PMID: 6322363
  61. Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400- and 800-mg doses and observations at higher doses.
    Am J Med. 1988 Mar;84(3 Pt 2):603-10 PMID: 3279775
  62. Azole antifungal agents: emphasis on new triazoles.
    Antimicrob Agents Chemother. 1988 Jan;32(1):1-8 PMID: 2831809
  63. Cryptococcal meningitis in the acquired immunodeficiency syndrome (AIDS): successful treatment with fluconazole after failure of amphotericin B.
    Ann Intern Med. 1988 Mar;108(3):384-5 PMID: 2829678
  64. Eradication of Candida burn wound septicemia in massively burned patients.
    J Trauma. 1988 Feb;28(2):140-5 PMID: 3279219
  65. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B.
    J Infect Dis. 1983 May;147(5):939-45 PMID: 6842027
  66. Synergistic action of amphotericin B and rifampin against Rhizopus species.
    Antimicrob Agents Chemother. 1987 Nov;31(11):1775-8 PMID: 3435124
  67. Effects of subconjunctival pimaricin in experimental keratomycosis.
    Am J Ophthalmol. 1973 May;75(5):790-4 PMID: 4574748
  68. In vitro studies with combinations of 5-fluorocytosine and amphotericin B.
    Antimicrob Agents Chemother. 1975 Aug;8(2):117-21 PMID: 1101814
  69. Neurotoxicity of amphotericin B methyl ester in dogs.
    Toxicol Pathol. 1988;16(1):1-9 PMID: 3375743
  70. The role of chemotherapy in the management of fungal endocaridits following homograft valve replacement.
    Postgrad Med J. 1979 Sep;55(647):629-31 PMID: 523354
  71. Comparative in vitro activity of LY121019 and amphotericin B against clinical isolates of Candida species.
    Eur J Clin Microbiol Infect Dis. 1988 Feb;7(1):80-1 PMID: 3132386
  72. A comparison of the efficacy of itraconazole, amphotericin B and 5-fluorocytosine in the treatment of Aspergillus fumigatus endocarditis in the rabbit.
    J Antimicrob Chemother. 1987 Nov;20(5):719-24 PMID: 2828301
  73. Effect of amphotericin B and rifampin against Coccidioides immitis in vitro and in vivo.
    Antimicrob Agents Chemother. 1976 Mar;9(3):406-13 PMID: 1259400
  74. Membrane-to-membrane transfer of lipophilic drugs used against cancer or infectious disease.
    Ann N Y Acad Sci. 1987;507:89-103 PMID: 3442369
  75. Treatment of histoplasmosis and blastomycosis.
    Chest. 1988 Apr;93(4):848-51 PMID: 3280262
  76. In vitro effects of fluconazole (UK-49,858) and ketoconazole on mouse lymphocyte proliferation and on Candida blastospore destruction by human polymorphonuclear leukocytes.
    Int J Immunopharmacol. 1988;10(2):169-73 PMID: 2836326
  77. Combined amphotericin B-flucytosine therapy in Aspergillus pneumonia.
    JAMA. 1979 Jun 1;241(22):2418-9 PMID: 374761
Article Info
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
Abbr.
Eur J Clin Microbiol Infect Dis
ISSN
0934-9723
DOI
10.1007/BF01963469
Published
1989-04-00
Pages
352-61
Language
English
Region
Germany
NLM ID
8804297
Subset
IM
External Links
PubMed source DOI: 10.1007/BF01963469 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2